| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.008 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.009 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.009 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.41 | 0.01 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | AZD0530 | FIMM | pan-cancer | AAC | 0.4 | 0.01 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |